http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20000016731-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8268e39ce70ff2ad19742e2a21d5a90c |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-111 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2799-022 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 |
| filingDate | 1997-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e0924371c539eb8f1b4c4177f3eaccb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23f56ba88d84890b306381f111f2cc09 |
| publicationDate | 2000-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20000016731-A |
| titleOfInvention | How to inhibit II synthesis |
| abstract | The present invention relates to expressible reverse gene constructs and oligonucleotides characterized by having the ability to hybridize with the Ii mRNA molecule to inhibit translation of the Ii mRNA molecule. These compositions are generally referred to as inhibitors of Ii expression. The invention also relates to MHC class II-positive antigen presenting cells containing inhibitors of Ii expression. Particularly important classes of MHC class II-positive antigen presenting cells are malignant MHC class II-positive antigen presenting cells (eg leukemia, lymphoma and melanoma). The invention also relates to a method of revealing an autocrystalline peptide bound to an MHC class II protein on the surface of an MHC class II-positive antigen presenting cell. In this method, specific inhibitors of Ii synthesis are introduced into MHC class II-positive antigen expressing cells. Specific inhibitors act directly or indirectly by double molecule formation with mRNA encoding Ii. Formation of the double molecule acts to inhibit Ii synthesis at the translation level. The present invention also includes therapeutic methods for malignant treatment in MHC class II-positive antigen presenting cells, and autocrystalline peptides isolated from MHC class II-positive antigen presenting cells. |
| priorityDate | 1996-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 152.